Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ibutilide
- Development stage
- Approved
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Ibutilide is a class III antiarrhythmic drug used intravenously for the rapid conversion of atrial fibrillation and atrial flutter of recent onset to normal sinus rhythm. Its primary mechanism of action is the prolongation of cardiac action potential duration, mainly by blocking the rapid component of the delayed rectifier potassium current (I_Kr) and activating a slow inward sodium current, which increases cardiac refractoriness. Ibutilide is structurally related to sotalol and is administered as an intravenous solution due to poor oral bioavailability. It was developed by Pharmacia & Upjohn (now part of Pfizer) and is marketed under the brand name Corvert[1][5][7][8].
- Brand names
- Corvert
- Other names
- ibutilide fumarate
02
Targets
CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)Cardiac late sodium currentKCNH2 (Voltage-gated potassium channel subfamily H member 2)NeuraminidaseNaV (Voltage-gated sodium channels)
Beyond the preview
Go deeper on ibutilide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ibutilide.